Cancer

Title
The Study of the Experimental Drug AG-003 in Patients With Advanced Kidney Cancer
Trial Number
204936121912
Number of Participants
700
Principal Investigator

Joseph Clark

M.D.
Hematology/Oncology
Professor
Eligibility

Patients must be age = 18 years, and have the following: advanced disease, histologically assessed as RCC, with a component of clear cell histology; measurable metastatic disease that can be monitored throughout the course of the study participation per RECIST 1.1; patients who are candidates for a first-line therapy initiating with sunitinib -Time from diagnosis to treatment life expectancy of 6 months or greater;
resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade = 1 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Purpose

You are being asked to participate in this study because you have newly diagnosed advanced kidney cancer and you have previously consented to allow for collection of your tumor sample, which may be used to make a personalized experimental drug for you called AGS-003.

Enrollment

(708) 327-3221

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.